TWD 91.2
(0.0%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 56.05 Million TWD | -0.01% |
2022 | 56.06 Million TWD | -9.75% |
2021 | 62.11 Million TWD | -2.86% |
2020 | 63.94 Million TWD | -13.92% |
2019 | 74.28 Million TWD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 52.11 Million TWD | -5.18% |
2024 Q2 | 43.06 Million TWD | 0.0% |
2023 Q3 | 56.05 Million TWD | -6.56% |
2023 Q4 | 56.05 Million TWD | 0.0% |
2023 FY | 56.05 Million TWD | -0.01% |
2023 Q2 | 59.99 Million TWD | 0.0% |
2023 Q1 | 59.98 Million TWD | 7.01% |
2022 Q3 | 56.06 Million TWD | 0.0% |
2022 Q4 | 56.06 Million TWD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Allied Biotech Corporation | 72.02 Million TWD | 22.169% |
GeneFerm Biotechnology Co., Ltd. | 76.14 Million TWD | 26.385% |
Easywell Biomedicals, Inc. | 330.44 Million TWD | 83.036% |
TTY Biopharm Company Limited | 403.04 Million TWD | 86.092% |
Synmosa Biopharma Corporation | 1.45 Billion TWD | 96.157% |
Orient EuroPharma Co., Ltd. | 2.2 Billion TWD | 97.455% |
Center Laboratories, Inc. | 4.42 Billion TWD | 98.734% |
Tien Liang BioTech Co., Ltd. | 377 Thousand TWD | -14769.231% |
Orient Pharma Co., Ltd. | 323.73 Million TWD | 82.684% |
InnoPharmax Inc. | 5.38 Million TWD | -940.791% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 100.83 Million TWD | 44.405% |
Excelsior Biopharma Inc. | 300.25 Million TWD | 81.33% |
DV Biomed Co., Ltd. | 315.74 Million TWD | 82.246% |
Foresee Pharmaceuticals Co., Ltd. | 13.11 Million TWD | -327.427% |
Handa Pharmaceuticals, Inc. | 7.67 Million TWD | -630.765% |
UniPharma Co., Ltd. | - TWD | -Infinity% |
Anxo Pharmaceutical Co., Ltd. | 499.69 Million TWD | 88.782% |
Alar Pharmaceuticals Inc. | 138 Thousand TWD | -40521.014% |
Mercury Biopharmaceutical Corporation | 41.66 Million TWD | -34.532% |
Bioray Biotech Co., Ltd | 65.65 Million TWD | 14.619% |
TSH Biopharm Corporation Limited | - TWD | -Infinity% |